臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"wu s g"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 61-85 / 224 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-02-05T07:26:09Z	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1	Kuei-Pin Chung;Huang Y.-L.;Chen Y.-J.;Juan Y.-H.;Hsu C.-L.;Nakahira K.;Huang Y.-T.;Lin M.-W.;Wu S.-G.;Shih J.-Y.;Chang Y.-L.;Yu C.-J.; KUEI-PIN CHUNG; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; Yu C.-J.
臺大學術典藏	2021-01-05T00:56:38Z	Acute cytomegalovirus pneumonitis in patient with lymphomatoid granulomatosis	Wu S.-G.; Tsai T.-H.; SHANG-JU WU
臺大學術典藏	2020-12-29T05:33:28Z	Critical illness polyneuromyopathy in a patient with disseminated cryptococcal infection	Yang P.-C.; Kuo P.-H.; HSIN-YUN SUN; Wu J.-Y.; Wu S.-G.
臺大學術典藏	2020-12-02T02:34:38Z	Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation	Wu S.-G.;Shih J.-Y.;Yu C.-J.;Pan-Chyr Yang; Wu S.-G.; Shih J.-Y.; Yu C.-J.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:34Z	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response	Wu J.-Y.;Wu S.-G.;Yang C.-H.;Gow C.-H.;Chang Y.-L.;Yu C.-J.;Shin J.-Y.;Pan-Chyr Yang; Wu J.-Y.; Wu S.-G.; Yang C.-H.; Gow C.-H.; Chang Y.-L.; Yu C.-J.; Shin J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:33Z	Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma	Wu S.-G.; Gow C.-H.; Yu C.-J.; Chang Y.-L.; Yang C.-H.; Hsu Y.-C.; Shih J.-Y.; Lee Y.-C.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:31Z	First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer	Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Pan-Chyr Yang; Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:29Z	Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern	Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; Yu C.-J.; Tsai M.-F.; Shih J.-Y.; Pan-Chyr Yang; Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; Yu C.-J.; Tsai M.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:24Z	Critical illness polyneuromyopathy in a patient with disseminated cryptococcal infection	Wu J.-Y.; Wu S.-G.; Sun H.-Y.; Kuo P.-H.; Pan-Chyr Yang; Wu J.-Y.; Wu S.-G.; Sun H.-Y.; Kuo P.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:23Z	Successful weaning after plasma exchange for polyneuropathy related to POEMS syndrome	Wu S.-G.; Kuo P.-H.; Pan-Chyr Yang; Wu S.-G.; Kuo P.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:10Z	Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations	Wu J.-Y.;Wu S.-G.;Yang C.-H.;Chang Y.-L.;Chang Y.-C.;Hsu Y.-C.;Shih J.-Y.;Pan-Chyr Yang; Wu J.-Y.; Wu S.-G.; Yang C.-H.; Chang Y.-L.; Chang Y.-C.; Hsu Y.-C.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:09Z	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations	Wu S.-G.; Yang C.-H.; Yu C.-J.; Lee J.-H.; Hsu Y.-C.; Chang Y.-L.; Shih J.-Y.; Pan-Chyr Yang; Wu S.-G.; Yang C.-H.; Yu C.-J.; Lee J.-H.; Hsu Y.-C.; Chang Y.-L.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:04Z	Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma	Tsai T.-H.; Wu S.-G.; Chang Y.-L.; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; PAN-CHYR YANG; Shih J.-Y.
臺大學術典藏	2020-12-02T02:34:03Z	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with Wild-type EGFR	Wu S.-G.; Kuo Y.-W.; Chang Y.-L.; Shih J.-Y.; Chen Y.-H.; Tsai M.-F.; Yu C.-J.; Yang C.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:34:01Z	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer	Tsai T.-H.; Su K.-Y.; Wu S.-G.; Chang Y.-L.; Luo S.-C.; Jane I.-S.; Yu C.-J.; Yue S.-L.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:59Z	Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR	Chung K.-P.; Wu S.-G.; Wu J.-Y.; Yang J.-H.; Yu C.-J.; Wei P.-F.; Shih J.-Y.; Pan-Chyr Yang; Chung K.-P.; Wu S.-G.; Wu J.-Y.; Yang J.-H.; Yu C.-J.; Wei P.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:52Z	Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis	Wu S.-G.; Hu F.-C.; Chang Y.-L.; Lee Y.-C.; Yu C.-J.; Chang Y.-C.; Wu J.-Y.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:49Z	Survival of lung adenocarcinoma patients with malignant pleural effusion	Wu S.-G.; Yu C.-J.; Tsai M.-F.; Liao W.-Y.; Yang C.-H.; Jan I.-S.; PAN-CHYR YANG; Shih J.-Y.; Wu S.-G.; Yu C.-J.; Tsai M.-F.; Liao W.-Y.; Yang C.-H.; Jan I.-S.; PAN-CHYR YANG; Shih J.-Y.
臺大學術典藏	2020-12-02T02:33:45Z	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations	Chen Y.-F.;Hsieh M.-S.;Wu S.-G.;Chang Y.-L.;Shih J.-Y.;Liu Y.-N.;Tsai M.-F.;Tsai T.-H.;Yu C.-J.;Yang J.C.-H.;PAN-CHYR YANG; Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:39Z	Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer	Lin Y.-T.;Wang Y.-F.;Yang J.C.-H.;Yu C.-J.;Wu S.-G.;Shih J.-Y.;Pan-Chyr Yang; Lin Y.-T.; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:29Z	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway	Tsai M.-F.; Chang T.-H.; Wu S.-G.; Yang H.-Y.; Hsu Y.-C.; Pan-Chyr Yang; Shih J.-Y.; Tsai M.-F.; Chang T.-H.; Wu S.-G.; Yang H.-Y.; Hsu Y.-C.; PAN-CHYR YANG; Shih J.-Y.
臺大學術典藏	2020-12-02T02:33:26Z	Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations	Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Pan-Chyr Yang; Shih J.-Y.; Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; PAN-CHYR YANG; Shih J.-Y.
臺大學術典藏	2020-12-02T02:33:23Z	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients	Wu S-G.; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; Yu C.-J.; Pan-Chyr Yang; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y.; Wu S-G.; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; Yu C.-J.; PAN-CHYR YANG; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y.
臺大學術典藏	2020-12-02T02:33:21Z	Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma	Shih J.-Y.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Pan-Chyr Yang; Shih J.-Y.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; PAN-CHYR YANG
臺大學術典藏	2020-12-02T02:33:19Z	The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition	Wu S.-G.; Chang Y.-L.; Yu C.-J.; Pan-Chyr Yang; Shih J.-Y.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; PAN-CHYR YANG; Shih J.-Y.

顯示項目 61-85 / 224 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51366706 線上人數 : 850 教育部委託研究計畫計畫執行:國立臺灣大學圖書館